Telmisartan in patients with mild/moderate hypertension and chronic kidney disease

Clinical Nephrology

Volumn 63, Issue 4, 2005, Pages 250-257

  Sharma, A M ^a,d   Hollander, A ^b   Koster J ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiotensin II receptor blocker; Chronic kidney disease; Hemodialysis; Hypertension; Telmisartan

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINOXIDIL; PLACEBO; TELMISARTAN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COUGHING; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PROTEINURIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYNCOPE;

EID: 17444417474     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP63250     Document Type: Article

References (25)

1. Bakris GL 2003 Who should be treated with combination therapy as initial treatment for hypertension? J Clin Hypertens 5: 21-28
2. Barnett AH, Bain SC, Bouter P et al 2004 Angiotensin receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961
3. Böhm M, Lee M, Kreutz R et al 1995 Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 13: 891-899
4. Brenner BM, Cooper ME, de Zeeuw D et al 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869
5. Chobanian AV, Bakris GL, Black HR et al 2003 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560-2572
6. Cice G, Di Benedetto A, Cerare S et al 2004 Unexpected heart rate reduction and antihypertensive efficacy of telmisartan in haemodialysis patients (abstract). XLI Congress of the European Renal Association. Lisbon, Portugal
7. Cushman WC 2003 The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens 5: 14-22
8. Doulton TW, MacGregor GA 2004 Blood pressure in haemodialysis patients: the importance of the relationship between the renin-angiotensin-aldosterone system, salt intake and extracellular volume. J Renin Angiotensin Aldosterone Syst 5: 14-22
9. Gavras HP 2001 Issues in hypertension: drug tolerability and special populations. Am J Hypertens 14: 231S-236S
10. Hannedouche T, Chanard J, Baumelou B et al 2001 Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2: 246-254
11. Hollenberg NK, Swartz SL, Passan DR et al 1979 Increased glomerular filtration rate after converting enzyme inhibition in essential hypertension. N Engl J Med 301: 9-12
12. Lacourcière Y, the Telmisartan Cough Study Group 1999 The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int J Clin Pract 53 99-103
13. Levey AS, Coresh J, Balk E et al 2003 National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-147
14. Lewis EJ, Hunsicker LG, Clarke WR et al 2001 Reno-protective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 851-860
15. Parving HH, Lehnert H, Bröchner-Mortensen J et al 2001 The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878
16. Schiffrin EL 2002 Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 113: 409-418
17. Sharpe M, Jarvis B, Goa KL 2001 Telmisartan: a review of its use in hypertension. Drugs 61: 1501-1529
18. Sica DA, Gehr TWB 2002 The pharmacokinetics and pharmacodynamics of angiotensin receptor blockers in end-stage renal disease. J Renin Angiotensin Aldosterone Syst 2I: 247-254
19. Simon SR, Black HR, Moser M et al 1992 Cough and ACE inhibitors. Arch Intern Med 152: 1698-1700
20. 14C]telmisartan in healthy volunteers. J Clin Pharmacol 40: 1312-1322
21. Stangier J, Su CAPF, Brickl R et al 2000b Pharmacokinetics of single-dose telmisartan 120 mg given during and between haemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 40: 1365-1372
22. Viberti G, Wheeldon NM 2002 Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106: 672-678
23. Weinbergová O, Metelka R, Vymětal J et al 2004 Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency. Biomed Papers 148: 69-73
24. Wienen W, Audeval-Gerard C, Champeroix P et al 1999 Antihypertensive and renoprotective effects of telmisartan after long term treatment in hypertensive (D) diabetic rats (abstract). J Hum Hypertens 13 (Suppl 3): S13
25. Wienen W, Entzeroth M, van Meel JCA et al 2000 A review on telmisartan: a novel, long-acting angiotensin II receptor antagonist. Cardiovasc Drug Rev 18: 127-156